ZIVO vs. CRBP, ANRO, SAVA, GNLX, ELDN, IVVD, ACTU, PEPG, FATE, and CCCC
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Corbus Pharmaceuticals (CRBP), Alto Neuroscience (ANRO), Cassava Sciences (SAVA), Genelux (GNLX), Eledon Pharmaceuticals (ELDN), Invivyd (IVVD), Actuate Therapeutics (ACTU), PepGen (PEPG), Fate Therapeutics (FATE), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs. Its Competitors
ZIVO Bioscience (NASDAQ:ZIVO) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.
Corbus Pharmaceuticals has a consensus price target of $45.43, suggesting a potential upside of 135.14%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than ZIVO Bioscience.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ZIVO Bioscience's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.
In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Corbus Pharmaceuticals and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat Corbus Pharmaceuticals' score of 0.67 indicating that ZIVO Bioscience is being referred to more favorably in the media.
ZIVO Bioscience has higher revenue and earnings than Corbus Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ZIVO Bioscience has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500.
Summary
Corbus Pharmaceuticals beats ZIVO Bioscience on 8 of the 15 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 10/17/2025 by MarketBeat.com Staff
